# Phibro Animal Health

> Phibro Animal Health develops, manufactures and sells medicines, vaccines, nutritional specialties and minerals for livestock, aquaculture and companion animals. Its business combines product sales with technical support for producers, feed companies, distributors and veterinarians, alongside ethanol processing aids and specialty chemicals.

- **Founded:** 1946
- **Headquarters:** Teaneck, United States
- **Products:** Medicated feed additives and water-soluble medicines, Animate, OmniGen, Tailor-Made autogenous vaccines and MVP adjuvants, Mineral Nutrition
- **Notable:** Completed its Nasdaq IPO in 2014., Completed the Zoetis medicated feed additive and selected water-soluble product acquisition on October 31, 2024., Reported fiscal 2026 net sales growth of 17% and net income of US$99.7 million.

## Products & services

- **Medicated feed additives and water-soluble medicines** — Veterinary medicines delivered through feed or water; the acquired portfolio includes brands such as Aureomycin and Terramycin. Availability and approved uses vary by country.
- **Animate** — An anionic mineral nutritional specialty used in pre-calving dairy nutrition programs to support calcium metabolism. Acquired in 2011.
- **OmniGen** — Nutritional specialty products formulated to support immune function in dairy cattle; OmniGen-AF was acquired in 2012.
- **Tailor-Made autogenous vaccines and MVP adjuvants** — Customized veterinary vaccines, diagnostic support and vaccine formulation ingredients. Phibro acquired MVP Laboratories in 2016.
- **Mineral Nutrition** — Trace minerals, organic mineral forms, premixes and related ingredients for animal diets, supported by Dynamic Quality Assurance.
- **Direct-fed microbials** — Beneficial microbial feed ingredients, including Bacillus-based products intended to support livestock gut health.
- **Phibro Aqua** — Fish health management, diagnostics, vaccines, nutrition and research capabilities for aquaculture producers.
- **KinetX yeast solutions** — Ethanol fermentation yeasts developed with Ingenza, including thermotolerant strains that secrete glucoamylase. Partnership described publicly in 2023.
- **Rejensa** — Supplemental joint-care chews for dogs; Phibro entered companion animal products with Rejensa in 2019.
- **Restoris** — Canine dental device marketed as a piezoelectric dental gel; launched in October 2025.
- **PhibroChem and Performance Products** — Specialty chemical ingredients and distribution for personal care, coatings, metal finishing and industrial markets.

## Achievements

- Completed its Nasdaq IPO in 2014.
- Completed the Zoetis medicated feed additive and selected water-soluble product acquisition on October 31, 2024.
- Reported fiscal 2026 net sales growth of 17% and net income of US$99.7 million.

## Latest updates

- **2026-08** — Reported fiscal 2026 results and fiscal 2027 sales guidance of US$1.55 billion to US$1.60 billion; guidance is a forecast.
- **2026-08** — Announced planned Chicago Heights production shutdown for summer 2027, affecting approximately 100 employees, with products transferred to other facilities and contract manufacturers.
- **2026-07** — Daniel (Dani) Bendheim became President and CEO on July 1; Jack Bendheim became Executive Chairman.
- **2026-06** — Phibro Forward, its three-year company transformation program, formally concluded on June 30.
- **2025-10** — Launched Restoris in canine dental care.

## Links

- Website: https://www.pahc.com/
- LinkedIn: https://www.linkedin.com/company/phibro-animal-health/
- YouTube: https://www.youtube.com/channel/UC1inkwwdTJfWISQfQpcBaLA
- Facebook: https://www.facebook.com/PhibroAnimalHealth/

---

Profile page: https://yespress.io/phibro-animal-health
Published by YesPress — https://yespress.io
Last updated: 2026-10-23